The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients

Abbott

Overview

To determine whether clarithromycin is safe and effective in preventing disseminated Mycobacterium avium Complex in HIV-infected patients with CD4 counts \<= 100 cells/mm3.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Mycobacterium Avium-intracellular Infection HIV Infections

Interventions

ClarithromycinDRUG

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria Patients must have: * HIV infection. * CD4 count \<= 100 cells/mm3. * No evidence of MAC. * Life expectancy of at least 6 months. Exclusion Criteria Concurrent Medication: Excluded: * Certain restricted drugs (details not available). Patients with the following prior conditions are excluded: History of allergy or hypersensitivity to macrolides. Active substance abuse or other conditions that would affect study compliance.

Locations (22)

Univ of Arizona / Health Science Ctr

Tucson, Arizona, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.